These 3 Risky Stocks Could Be Sitting on 100% Upside

These 3 Risky Stocks Could Be Sitting on 100% Upside

Nathan Reiff, MarketBeat

Mon, September 7, 2026 at 6:35 PM GMT+3 5 min read

Key Points

• Interested in Red Cat Holdings, Inc.? Here are five stocks we like better.

• Analysts believe Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources could each at least double in value, though all carry elevated risk.

• Red Cat posted 520% year-over-year revenue growth and relies on Army contracts for about half its sales, with analysts projecting shares could climb 115% to $18.

• Taysha's Rett syndrome gene therapy and Solaris's Warintza copper project represent single high-stakes bets whose success could drive substantial stock gains.

With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some long-established firms have posted surprising rallies in recent trading sessions, a combination of consumer reticence and stretched valuations means that many go-to investments may not see much near-term growth.

Investors willing to accept some additional risk might look to companies in the robotics, clinical-stage biotech, and mineral exploration spaces. These industries all contain firms analysts believe could at least double in value in the future. Of course, along with these lofty predictions comes a caveat: these firms carry some degree of risk, often elevated beyond a market-wide norm to levels that may not be comfortable for investors.

→ 3 Stocks With September Catalysts Investors Shouldn't Ignore

Red Cat's Drone Business Faces Challenges But Massive Growth Potential

Once high-flying, drone stocks like Red Cat Holdings Inc. (NASDAQ: RCAT) have come back down to earth in 2026.

Red Cat offers a small-cap perspective on drone technology and is somewhat less stable than some other companies in the space, owing to its difficult history with quarterly losses. This includes a quarterly loss per share of 26 cents for Q2 2026, 5 cents wider than analysts had predicted.

→ Why Hewlett Packard Enterprise's Sell-Off May Not Last

Still, there may be opportunities for asymmetric growth here. The company relies heavily on government contracts, with Army revenue accounting for about 50% of its sales in the first half of 2026.

These tend to be longer-term agreements that can provide some steadiness to sales figures, particularly for smaller firms like RCAT. At the same time, Red Cat has enjoyed massive revenue growth—520% year over year (YOY) for Q2 2026 alone—as well as improving gross margins, increases to production volume, and better efficiency overall.

→ 3 Earnings Season Winners That Analysts Can't Stop Upgrading

While operating expenses are rising, presenting a continued challenge to Red Cat's profitability struggles, it's arguable that the firm's areas of momentum could outpace those concerns. This may be why analysts are so optimistic about RCAT stock, estimating that it will climb by 115% to $18 per share.

Taysha Bets Big on a Single Drug, But There Are Many Positive Signs

Investor interest has been building surrounding Taysha Gene Therapies Inc. (NASDAQ: TSHA), a clinical-stage biotech firm that creates gene therapies for diseases of the central nervous system. The company is coming off an exciting second quarter that saw progress both on the drug development front and in terms of Taysha's manufacturing capacity, the latter thanks to a partnership with Catalent.

Taysha's candidate TSHA-102 is moving toward a biologics license application (BLA) with the U.S. FDA and could become the first disease-modifying gene therapy approved for Rett syndrome, a rare neurodevelopmental disorder.

Specifically, the company is waiting on results from the REVEAL pivotal study, but clinical data so far have been encouraging. Rett syndrome has no approved therapy to address the underlying genetic cause, making TSHA-102 a potential one-of-a-kind treatment.

Of course, with only a single major drug candidate in development, any anticipated gains for Taysha shares will rely on the success of TSHA-102. This makes the company a classic high-risk, high-reward play in the biotech space.

Solaris Has a Single Major Mining Prospect, But It's a Good One

Canadian mineral exploration outfit Solaris Resources (NYSEAMERICAN: SLSR) is essentially a development-stage copper mining company with a world-class mining asset in the Warintza project. The big question for this company is whether that project will eventually reach construction and production. If so, this Ecuadorian site could become one of the top global copper mines. With copper remaining an essential metal for electrification, EVs, AI-related infrastructure, and more, demand for this resource is likely to stay high.

Solaris doesn't actually have any producing mines to generate cash flow as of now. This is the element of the company's story that makes it a high-risk venture. In many respects, it is operationally untested. However, an upcoming feasibility study should help to give investors a better sense of just how valuable the Warintza project may be, and—if the results are strong—could give SLSR shares a big boost.

Even still, there are many uphill battles for Solaris, including permitting, construction, financing risk, political uncertainty, and the potential for copper prices to shift. Analysts do see a path higher, however. A winning combination of a strong feasibility study, on-schedule permit approvals, successful financing, and sustained copper demand could send Solaris climbing 118% above its current price. If any of these pieces does not fall into place, though, the company may very well be in trouble.

The article "These 3 Risky Stocks Could Be Sitting on 100% Upside" was originally published by MarketBeat.

View MarketBeat's top stocks for September 2026.